

**EUROPEAN
CURRICULUM VITAE
FORMAT**



PERSONAL INFORMATION

| | |
|-------------------------|---|
| Name | TONI IBRAHIM |
| Address | Corso della Repubblica, 49 47121 Forlì (FC) Italy |
| Telephone | |
| E-mail | |
| Nationality | Italian |
| Place and Date of birth | LEBANON, 01 SEP 1968 |

WORK EXPERIENCE

- Participant in a course in Cellular Biology at the Laboratory of Cellular Biology (Istituto di Anatomia Umana Normale, University of Ferrara, Italy) during the academic year 1990-1991
- Post-graduate training at S. Anna hospital, Ferrara, Italy: Medical Oncology Dept, General Surgery, Institute of Clinical Obstetrics & Gynecology, A&E, and Laboratory of the Institute of Anatomy and Histology (1996-1997)
- Various freelance and fixed-term contracts (Istituto Oncologico Romagnolo) at Pierantoni Hospital, Forlì, Italy: Medical Oncology Dept - Medical Oncologist with clinical (inpatient, Day Hospital, outpatient clinic, and home care) and research responsibilities (phase I-IV, in Good Clinical Practice) (1997-2008)
- Freelance contract with AIL (Italian Association against Leukemia, Forlì-Cesena branch), treating Oncohaematology patients (blood transfusions etc) in the Forlì province, Italy (Oct-Dec 2001)
- Medical Director of Sanibel Srl Polyclinic, Meldola (FC), Italy, a

subsidized private health facility with the National Health Service (Jul 2003-Feb 2005)

- Founder and Head of the Osteoncology Center, IRST-IRCCS (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Meldola (20 Jan 2005-09 May 2021).
- Founder and Head of Rare Tumors Center , IRST-IRCCS (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Meldola (Jan 2011-09 May 2021).
- Head of Immunotherapy, Somatic Cellular Therapy and Biobank, IRST-IRCCS (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Meldola (April 2020-09 May 2021).
- Permanent contract form Feb 2008 with IRST- IRCCS and Head of the Osteoncology and Rare Tumors Center (CDO-TR), until May 09 th 2021, which include 6 Oncologists and 7 Lab Researchers. The CDO-TR is a Center of Excellence for ISO (Italian Society of Osteoncology) criteria and member of National Network of Osteoncology and Rare Tumors and EURACAN (EUropean RARE CANcers). Head of the Unit (April 2020- May 2021): Immunotherapy, Somatic Cellular Therapy and Biobank (ITCB) which include 3 Oncologists, 5 Lab reasearchers, the Immuno-Gene Therapy Factroy include 4 biologists and 4 lab tecnicians, The Biobank include 3 biologists and 1 lab tecnician. Dr Ibrahim coordinate 32 professionals. The CDO-TR and ITCB offering mono and multidisciplinary assistance, basic and translational research and training program
- Coordinator of the multidisciplinary group of Head and Neck Cancer and Rare Tumors of The Comprehensive Cancer Care Network- AUSL Romagna/IRST- IRCCS, of Romagna, Italy. (15 Feb 2018- 09 May 2021)
- From May 10 th 2021, at IRCCS Istituto Ortopedico Rizzoli (Rizzoli Orthopedic Institute IOR), Bologna: Director of “Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit” which include 6 Oncologists, 11 Lab Researchers and 2 Study Coordinators; Coordinator of Oncological Networks and Clinical Pathways and Translational Oncological Research at IOR.
- Visiting Scientist from 07/02/12 to 07/28/12 at The Methodist Hospital Research Institute, Houston- Texas, USA , from 07/30/12 at 08/11/12 at Molecular Department, Princeton University, Princeton- New Jersey, USA and form 10/12/2014 at 10/22/2014 at the Urology department of Leiden University Medical center, The Netherlands.

EDUCATION AND TRAINING

- Degree in Biological Sciences (BSc) with Master (MSc) in Physiology (Lebanese University of Beirut, Lebanon, 1989)
- Degree in Medicine with Honours (110/110) (University of Ferrara, Italy, 1996)
- Specialization in Medical Oncology with Honours (50/50) (University of Ferrara, Italy, 2000)
- Admitted to practice and member of the Order of Physicians in the Forlì-Cesena Province, Italy (1997-present)
- Master of Science (MSc) degree in Osteoncolgy (University of Modena and Reggio Emilia, Italy, 2005)
- PhD in Experimental and Clinical Oncology (University of Modena and Reggio Emilia, Italy, 2009)
- Qualified to the management of Complex Structures of Healthcare at 9th dec 2015 at the University of Ferrara and the Emilia-Romagna Region

RESEARCH PUBLICATIONS AND EDITORIAL ACTIVITIES

Author and co-author of : over 400 scientific abstracts, 9 teaching materials, 166 scientific articles peer reviewed (H index 35 Google Scholar and 32 Scopus and web of science at 9th Oct 2022), editor of 2 books, author of 16 book chapters and 1 newspaper article relating to a national public health interest. Editor in *Frontiers in Oncology*, *Computational and Structural Biotechnology Journal*, *Materials Today and Biomedicines*. Reviewer of *Annals of Oncology*, *Cancer Letters*, *Future Oncology*, *Biomaterials*, *Tumor Biology*, *Aging*, *Biomacromolecules*, *Molecular Cancer*, *Nanomaterials*, *Therapeutics and Clinical Risk Management*, *Clinical & Experimental Metastasis*, *Int J Mol Science*, *Oncotarget*, *ACC Nano*, *Materials*, *International Journal of Cancer*, *Biomarker Insights*, *Journal of Functional Biomaterials*, *Endocrine*, *The Oncologist*, *Clinical Medicine Insights: Case Reports*, *Current Medical Research & Opinion*, *Scientific Reports*, *Cancers*, *OncoTargets and Therapy*, *Histochemistry and Cell Biology*, *Colorectal Cancer*, *Expert Opinion On Investigational Drugs*, *Journal of Functional Biomaterials*, *Medical Science Monitor*, *Clinical Medicine Insights: Endocrinology and Diabetes*, *Oncology Letters*, *Peer J*, *World Journal of Surgical Oncology and Pharmaceutics*.

European Research Council (ERC) Reviewer.

Reviewer of the National Science Center, Poland.

Registered in REPRISE (the Register of Scientific Experts set up at the MIUR, Italian Ministry of Instruction, University and Research) for the following sections: Applied research.

Patent: designation as inventor, EP application entitled “Engineered

nanovesicles and uses thereof' has been filed October 1, 2019.
Application no. is EP19200824.1.

Research calls won:

- 1) Italian Ministry of Health, 2006, RFPS-2006-6-341882 (Local PI): Research and management of patients with bone metastases.
- 2) AGENZIA ITALIANA PER IL FARMACO (AIFA) 2012 (Local PI). Clinical trial: "Studio prospettico, multicentrico, di fase III, randomizzato, di non inferiorità, di confronto di acido zoledronico (ZOMETA®) somministrato ogni 12 settimane verso ogni 4 settimane nel carcinoma non a piccole cellule del polmone (NSCLC) in pazienti con metastasi ossee – Protocollo ZEN" – code FARM9I37AY2.
- 3) Italian Ministry of Health (Conto Capitale Call 2015 as PI): CC-2015-2361049 Development and Validation of innovative nanosystems for breast cancer treatment.
- 4) AGENZIA ITALIANA PER IL FARMACO (AIFA) 2016 (Local PI): Clinical Trial "Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized Adrenocortical Carcinoma with high risk of recurrence (Trial ACACIA)". Code AIFA-2016-02364512
- 5) Ministero della Salute Italiano: Bando GR-2016-02364704. Title: An in vitro and ex vivo model of biomimetic regenerative devices to treat bone metastases and soft tissue tumors: BIOBOS PROJECT. PI: Laura Mercatali (Component of the group of Dr Toni Ibrahim)
- 6) Ministero della Salute Italiano: Bando GR-2016- 02364834 (Local PI) Randomized phase II study of Metronomic Cyclophosphamide vs Doxorubicin in Elderly Patients with Advanced Soft Tissue Sarcomas: the MetropholyS trial
- 7) Ministero dell'Istruzione, Università e della Ricerca Italiano (MIUR) (Domanda n. ARS01_00769, Programma Operativo Nazionale 2018 PON) (Local PI): Nanofotonica per nuovi approcci diagnostici e terapeutici in Oncologia e Neurologia - NeON".
- 8) Ministero della Salute Italiano: progetto RF-2018-12368004 (Principal Investigator and coordinator of the consortium): "A theraNostic approach to reduce local recurrence of MYxofibrosarcoma (HYdRA) "
- 9) POR-FESR EMILIA ROMAGNA 2014-2020. Bando 2018 Progetti di ricerca industriale strategica rivolti agli ambiti prioritari della Strategia di Specializzazione Intelligente. Principal Investigator and coordinator of the consortium. Progetto: "Sviluppo e validazione di biomateriali medicati nanostrutturati per il trattamento e la rigenerazione del tessuto Osseo metastatico – DINAMICA"
- 10) Ministero della Salute Italiano: Bando GR-2019-12370014. Autologous ECM-composed scaffolds and zebrafish PDXs for individualized Theranostics in rare neuroendocrine neoplasms (AVATAR). PI: Chiara Liverani (Component of the group of Dr Toni Ibrahim)

PERSONAL SKILLS AND COMPETENCES

- Until May 09 th, The Osteoncology and Rare Tumors Center (CDO-TR) includes on the staff over to Dr. Ibrahim, 6 medical oncologists and 7 Lab Researchers. Dr Ibrahim then manages human and economic resources. In particular:
 - 1) shows the number of patients treated at the CDO-TR in the following years: 2011 (1584 patients), 2012 (1753), 2013 (1993), 2014 (2405), 2015 (3139), 2016 (3149), 2017 (3085), 2018 (2964) and 2019 (3444).
 - 2) the results of the assessment of achievement of management objectives (Assistance, Research and Training) and budgets conclusion: 2011 (100%); 2012 (100%); , 2013 (97%); 2014 (99%), 2015 (100%), 2016 (100 %), 2017 (100%), 2018 (100 %) and 2019 (100 %).From April 1st 2020, head of the Unit (ITCB): Immunotherapy, Somatic Cellular Therapy and Biobank (ITCB) which include 19 professionals. The CDO-TR and ITCB offering mono and multidisciplinary assistance, basic and translational research and training program
- Organized and realized the Italian national project “multidisciplinary management of bone metastasis: Osteoncology”
- Instituted the Osteoncology Center at Pierantoni Hospital, Forlì, and IRST- IRCCS, comprising a multidisciplinary team of 22 healthcare professionals involved in patient care, research (preclinical, translational and clinical) and teaching in bone cancer disease (Jan 2005- May 2021)
- Instituted the Rare Tumors Center at IRST- IRCCS, comprising a multidisciplinary team of healthcare professionals involved in patient care, research (preclinical, translational and clinical) and teaching in Rare Tumors (Sarcomas, Neuroendocrine Tumors, Head and Neck, Skin non melanoma and Neurologic tumors) (from Jan 2011 to May 2021)
- Co-Founder, Past president (2008-2014), member of the Advisory Board of the Italian Society of Osteoncology (ISO) (2014-2022) and actually is the president from Oct 22nd 2022 for 3 years
- Founder on 2016, of the Multidisciplinary Osteoncology School (MOS) at IRST, Meldola (Italy), with the main objective, to promoting theoretical and practical courses at IRST in mono/multidisciplinary assistance and translational research in Osteoncology.
- From 1996 to 2000 followed patients during the specialization in oncology with high dose chemotherapy and peripheral autologous stem cell transplantation. Subsequently followed these patients in oncology where he carried out his clinical activities.
- Founder member of the IMI (Italian Melanoma Intergroup)
- Honorary member of the Association for the Study of Psychology and Neuroscience, "G. M. Balzarini "
- Biology lecturer for 5th year students at a private Lebanese High School (École des Filles de la Charité) during the academic year 1989-90

- From 2007 to May 2021 at IRCCS- Istituto Romagnolo per lo Studio dei Tumori IRST Dino Amadori: Scientific Responsabile of Zebrafish Facility, Principal Investigator of 41 clinical and translational research studies and Co-Responsabile of Research Line 2: “ Development of Clinical and Biological (cellular and molecular) rational for innovative multicentric clinical studies of new drugs” of the three-year program of Research of IRST IRCCS-Meldola (Italy) submitted to the Italian Ministry of Health and Member of the “Scientific Medical Advisory Board” of IRST IRCCS- Meldola (Italy)
- From May 10 th 2021, at IRCCS Istituto Ortopedico Rizzoli (Rizzoli Orthopedic Institute IOR), Bologna: Director of “Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit” which include 6 Oncologists, 11 Lab Researchers and 2 Study Coordinators; Coordinator of Multidisciplinary Groups and Networks in Osteoncology and Sarcomas and Coordinator of Translational Oncologic Research at IOR.
- Member of Regional Board (Regione Emilia Romagna) of Rare Tumors
- Member of Head and Neck , Brain, Breast, Endocrine, and Soft tissue and Bone EORTC groups
- University lecturer, Master II level in Osteo-Oncology (Form III: The pathophysiology of bone and epidemiology in Osteo-Oncology), and part of the Master organizing committee (University of Modena and Reggio Emilia, Italy, 2004-2006)
- Author of the Associazione Italiana di Oncologia Medica (AIOM) guidelines: “Treatment of bone metastases, Thyroid Tumors, Soft Tissue sarcomas and GIST and Neuroendocrine Neoplasms”
- PhD lecturer in Osteo-Oncology (University Campus Bio-Medico, Rome) and in Oncology, Hematology and Pathology (University of Bologna)
- Tutor for 1 PhD student in Oncology/Haematology and Pathology (Bologna University) and 2 medical trainees in Oncology (Ferrara University)
- Participated in national and international conferences as chairman, organizer, rapporteur or lecturer
- Participated as a speaker at training courses for volunteers in patient assistance programs

| | |
|-------------------------------|---|
| MOTHER TONGUE | ARABIC |
| OTHER LANGUAGES | ITALIAN, FRENCH, ENGLISH |
| • Reading skills | Good |
| • Writing skills | Good |
| • Verbal skills | Good |
| SOCIAL SKILLS AND COMPETENCES | BOARD MEMBER OF A PARISH GROUP WITH THE AIM OF TRAINING AND VOLUNTEERING ACTIVITY |